101 articles with Immunovia
Immunovia AB announces that Patrik Dahlen, CEO of Immunovia, has purchased 6,860 shares for approximately SEK 675,000 over the stock exchange.
Immunovia AB announced that the member of the Board of Directors Peter Høngaard Andersen has almost doubled his shareholding in Immunovia by purchasing 2,730 shares, an investment of 297,570 SEK.
On 6th May 2021, the Annual General Meeting was held in Immunovia AB, 556730-4299. Due to the extraordinary situation following the COVID-19-pandemic, the AGM was carried out through advance voting pursuant to temporary legislation.
Immunovia AB announced that the following members of the Board of Directors have purchased shares in the company
Immunovia has today published its interim report for the period January 1 – March 31, 2021 . It is available on Immunovia's website .
Immunovia is launching its IMMray™ PanCan-d test in the US as a Laboratory Developed Test in Q2 2021.
Immunovia will publish the company's interim report for the period January 1 - March 31, 2021 on Wednesday, April 28, 2021 at 16:00 CET.
Immunovia reports improved test performance of IMMrayTM PanCan-d in detecting early stage pancreatic cancer in high risk symptomatic patients
Immunovia announced improved performance of its blood based IMMray™ PanCan-d biomarker signature together with CA 19-9, in a clinical retrospective study.
Immunovia reports positive results of the blinded clinical validation of IMMray™ PanCan-d blood test in USA
Stage I/II pancreatic cancers were detected with 98% specificity and 85% sensitivity in familial/hereditary risk group cohorts
Immunovia has today published the annual report for 2020. It is available on Immunovia's website .
Immunovia AB (publ) ("Immunovia") today published two new data sets in scientific poster formats, including results from the development phase of the Company's IMMray™ PanCan-d blood based test for early detection of pancreatic cancer.
Immunovia has today published its Full Year Report for January - December 2020 . It is available on Immunovia's website .
Immunovia's PanFAM-1 Prospective Study Gathers Over 3000 Familial Hereditary Pancreatic Cancer Risk Samples And Will Be Analysed In The Second Half Of 2021
According to the American Cancer Society, as many as 10% of pancreatic cancers are caused by familial and hereditary risk factors. PanFAM-1 is the largest prospective study to date, focusing on early diagnosis in high-risk individuals with Familial/Hereditary Pancreatic Cancer (FPC).
Immunovia is pleased to invite investors, analysts and media to a teleconference with web presentation on Wednesday, February 17, 2021 at 16:30 pm CET.
Immunovia AB provides an update on the status of the company's activities and as previously reported, Immunovia will initiate sales start in Q1 2021 of the company's first test, IMMray™ PanCan-d designed for early detection of pancreatic cancer.
Immunovia AB, ("Immunovia") announces today that Patrik Dahlen , CEO of Immunovia, has purchased 250,000 warrants of the 2020/2024 scheme for approximately 400 KSEK. His total holding now amounts to 45,000 shares and 250,000 warrants in Immunovia. The warrants have a subscription price per share of SEK 455 . Other management team
Immunovia AB (publ) ("Immunovia") today published the link to the company's third webinar in a series on IMMray™ PanCan-d, Immunovia's test for early detection of pancreatic cancer. The webinar will cover the IMMray™ PanCan-d verification study results and its clinical use, including feedback from experts in pancreatic cancer and pa
Immunovia AB (publ) ("Immunovia") a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, announced today that Julie Silber , Senior Director of Investor Relations has stepped down from her position to pursue other
Immunovia AB (publ) ("Immunovia") announced today that the following members of the Board of Directors have purchased shares in the company: Member Number of Shares Total Investment Ann-Christine Sundell 2,500 292,500 SEK Mimmi Ekberg 451
Immunovia invites investors, analysts and the media to a telephone conference with CEO Patrik Dahlen tomorrow, Thursday, December 3 , at CET 10:00 to address an article published on di.se on December 1 : Experts skeptical to Immunovia's bloodtest: "Would not count on it" ( Experter skeptiska till Immunovias blodtest: "Sk